Full text is available at the source.
Abstract
Incretin agonist therapies can reduce body weight by 10-20% and lower the risk of major adverse cardiovascular events.
- Incretin agonists, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, have shown substantial efficacy in weight reduction and cardiometabolic health.
- Clinical trials indicate these medications significantly decrease the risk of cardiovascular death, nonfatal myocardial infarction, and stroke.
- The cardiovascular benefits of these therapies are observed in both diabetic and non-diabetic patients and extend beyond just controlling blood sugar levels.
- Tirzepatide has demonstrated superior efficacy in weight loss compared to traditional GLP-1 monotherapy.
- Pharmacologic therapy is increasingly recognized as a vital component in managing cardiovascular risk associated with obesity.
Simplified